ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more
ISU Abxis Co. Ltd - Asset Resilience Ratio
ISU Abxis Co. Ltd (086890) has an Asset Resilience Ratio of 0.33% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how ISU Abxis Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down ISU Abxis Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩538.59 Million | 0.33% |
| Total Liquid Assets | ₩538.59 Million | 0.33% |
Asset Resilience Insights
- Limited Liquidity: ISU Abxis Co. Ltd maintains only 0.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ISU Abxis Co. Ltd Industry Peers by Asset Resilience Ratio
Compare ISU Abxis Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AGP Ltd
KAR:AGP |
Pharmaceuticals | 0.71% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
Annual Asset Resilience Ratio for ISU Abxis Co. Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for ISU Abxis Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.90% | ₩28.68 Billion | ₩160.23 Billion | -39.82pp |
| 2023-12-31 | 57.72% | ₩119.34 Billion | ₩206.74 Billion | +16.96pp |
| 2022-12-31 | 40.76% | ₩55.96 Billion | ₩137.27 Billion | +14.53pp |
| 2021-12-31 | 26.23% | ₩39.63 Billion | ₩151.09 Billion | +5.12pp |
| 2020-12-31 | 21.11% | ₩17.47 Billion | ₩82.75 Billion | -12.82pp |
| 2019-12-31 | 33.92% | ₩31.47 Billion | ₩92.76 Billion | +15.14pp |
| 2018-12-31 | 18.79% | ₩13.12 Billion | ₩69.84 Billion | -19.51pp |
| 2017-12-31 | 38.30% | ₩29.78 Billion | ₩77.77 Billion | +13.45pp |
| 2016-12-31 | 24.85% | ₩14.87 Billion | ₩59.84 Billion | -8.49pp |
| 2015-12-31 | 33.34% | ₩23.34 Billion | ₩70.00 Billion | +32.72pp |
| 2014-12-31 | 0.62% | ₩304.76 Million | ₩48.99 Billion | -- |